Fangzhou Inc. (6086) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 12.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 488
• Sector: Technology
• Sector Strength: 88
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.70
• Shares Outstanding: 1,340,267,500
• 10 Day Avg. Volume: 9,400,700
• 30 Day Avg. Volume: 12,674,740
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$4.00
• Price Target Upside: -5.66% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: HK$4.00 ▼(-5.66% Downside)

Fangzhou Inc.'s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While there are some positive technical indicators suggesting potential upward momentum, the company's ongoing financial challenges and lack of profitability are significant concerns.

Fangzhou Inc. Business Overview & Revenue Model

Company Description

Fangzhou Inc. provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. It offers H2H services, including online medical consultation services, e-prescription, and prescription refill services through mobile application; and healthcare products through online retail pharmacy service platform, as well as operates hospitals and offline pharmacies. The company was founded in 2015 and is based in Guangzhou, China.

How the Company Makes Money

Fangzhou Inc. generates revenue through multiple streams, primarily from the sale of its robotics and automation products, which includes both hardware and software solutions. The company also earns income through service contracts, providing maintenance and support for its products post-sale. Additionally, Fangzhou has established strategic partnerships with key players in various industries, allowing it to expand its market reach and leverage shared technologies. Revenue is further supplemented by consulting services offered to clients looking to integrate automation into their operations, enhancing their overall productivity and efficiency.

Fangzhou Inc. Financial Statement Overview

Summary

Fangzhou Inc. faces financial difficulties with persistent losses and high leverage. Despite revenue growth and improved cash management, profitability and balance sheet stability remain concerns.

Income Statement

Fangzhou Inc. shows a challenging financial performance with consistent net losses and negative EBIT and EBITDA margins over the years. The gross profit margin has slightly improved, but the net profit margin remains negative. Revenue growth is positive, indicating potential, but profitability remains a significant concern.

Balance Sheet

The balance sheet reflects a high debt burden relative to equity, as indicated by the negative stockholders' equity and high debt-to-equity ratio. The equity ratio is low, suggesting financial instability. However, the reduction in total liabilities and improvement in cash and cash equivalents are positive signs.

Cash Flow

Operating cash flow has improved, turning positive in the latest year, which is a positive development. However, free cash flow remains low, and the cash flow ratios indicate a struggle to convert income into cash. The company has managed to improve its cash position, but overall cash flow stability is weak.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.71B	2.43B	2.56B	2.12B
Gross Profit	515.94M	487.41M	441.20M	262.74M
EBITDA	-739.87M	-174.76M	-127.78M	-260.07M
Net Income	-854.88M	-196.79M	-445.73M	-366.34M
Balance Sheet
Total Assets	664.09M	521.37M	582.57M	426.54M
Cash, Cash Equivalents and Short-Term Investments	261.51M	146.32M	179.53M	103.56M
Total Debt	50.89M	49.72M	1.99B	1.70B
Total Liabilities	532.39M	2.42B	2.50B	2.07B
Stockholders Equity	131.70M	-1.90B	-1.92B	-1.64B
Cash Flow
Free Cash Flow	15.63M	16.63M	-65.42M	-262.72M
Operating Cash Flow	19.54M	22.28M	-59.28M	-246.43M
Investing Cash Flow	-111.51M	16.42M	16.65M	-5.21M
Financing Cash Flow	119.62M	-29.31M	125.88M	-12.77M

Fangzhou Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6086, the sentiment is Negative. The current price of 4.24 is below the 20-day moving average (MA) of 4.40, above the 50-day MA of 4.01, and above the 200-day MA of 4.19, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 46.21 is Neutral, neither overbought nor oversold. The STOCH value of 8.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6086.

Fangzhou Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	77 Outperform	HK$107.21B	25.80	14.27%	2.77%	-18.07%	-33.27%
1666	69 Neutral	HK$6.08B	13.09	―	4.13%	0.73%	-34.04%
2186	58 Neutral	HK$12.81B	30.02	3.33%	―	-2.54%	-48.74%
0020	48 Neutral	HK$105.97B	-28.64	-18.24%	―	17.96%	46.64%
6086	46 Neutral	―	―	―	―	―	―
1799	41 Neutral	HK$11.61B	-3.33	―	―	-32.78%	-152.00%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

Fangzhou Inc. Corporate Events

Fangzhou Inc. Reports Strong Financial Growth and AI Integration in H1 2025

Fangzhou Inc. reported strong financial results for the first half of 2025, achieving a net profit of RMB12.5 million, reversing a previous net loss. The company expanded its AI integration across its platform, enhancing its chronic disease management services. The user base grew to 52.8 million, with significant increases in monthly active users and partnerships with healthcare providers and pharmaceutical companies, indicating robust platform growth and strategic advancements.

The most recent analyst rating on (HK:6086) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

Fangzhou Inc. Schedules Board Meeting to Review Interim Results

Fangzhou Inc. has announced a board meeting scheduled for August 27, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters, which could impact the company’s financial strategy and stakeholder interests.

Fangzhou Inc. Announces Successful AGM Resolutions

Fangzhou Inc., a company incorporated in the Cayman Islands, announced the successful passing of all proposed resolutions at its Annual General Meeting held on June 19, 2025. Key resolutions included the re-election of directors, the re-appointment of KPMG as the auditor, and the granting of mandates to the directors to manage shares, all of which were approved with overwhelming support from shareholders.

Fangzhou Inc. Expands Nomination Committee with New Appointment

Fangzhou Inc., a company incorporated in the Cayman Islands, has announced the appointment of Ms. KANG Wei as a member of its Nomination Committee, effective June 18, 2025. This appointment expands the committee to four members, potentially enhancing the company’s governance and decision-making processes.

Fangzhou Inc. Announces Board Composition and Roles

Fangzhou Inc., a company incorporated in the Cayman Islands, announced the composition of its board of directors and the roles within its three board committees. The announcement provides clarity on the leadership structure, which includes Mr. XIE Fangmin as the Chairman and executive Director, along with other executive, non-executive, and independent non-executive directors. This update is significant for stakeholders as it outlines the governance framework and decision-making hierarchy, potentially impacting the company’s strategic direction and operational oversight.

Fangzhou Inc. Establishes Nomination Committee for Enhanced Governance

Fangzhou Inc., a company incorporated in the Cayman Islands, has outlined the terms of reference for its Nomination Committee. The committee, consisting of at least three members with a majority being independent non-executive directors, is responsible for overseeing the nomination process for board members. This move is aimed at ensuring a diverse and independent board composition, which is crucial for the company’s governance and strategic direction. The committee’s activities will be transparent, with its chairperson attending the annual general meeting to address shareholder queries.